Other substances

FN3A

An anti-RBD (SARS-CoV-2 Spike) monobody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

FN3A is a monobody - an alternative (non-antibody) affinity protein reagent derived from fibronectin type III domain (derived from the domain 10 of human fibronectin). It was identified using a phage display technique for its affinity for SARS-CoV-2 Spike protein RBD. The monobody can be fused with human IgG1 Fc. Although there are monobodies in clinical trials, this particular was envisaged rather to be developed into a diagnostic tool (Miller et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein
Spike protein Biophysical assay Protein factor In vitro 		in vitro binding assay; in vitro biophysical assay 4.67

Binds SARS-CoV-2 Spike RBD in vitro with a KD of ca. 5.56 nM. When fused to human IgG1 Fc, the monobody bound RBD in a dose-dependent manner.

 Feb/05/2021
Export (.csv)